Compare Stocks → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BLCMNASDAQ:CBIONASDAQ:CORVNASDAQ:IFRXNASDAQ:SVRA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLCMBellicum Pharmaceuticals$0.07-6.6%$0.08$0.06▼$1.31$727K1.3922,874 shs6,000 shsCBIOCatalyst Biosciences$0.77$0.19▼$8.69$291.29M1.05763,526 shs32,246 shsCORVCorrevio Pharma$0.42$0.41$0.21▼$2.79$27.80M0.085.35 million shsN/AIFRXInflaRx$1.39+2.2%$1.54$1.14▼$5.20$81.85M1.27237,628 shs146,063 shsSVRASavara$4.45+5.0%$4.94$1.78▼$5.70$614.76M0.77852,109 shs1.25 million shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLCMBellicum Pharmaceuticals0.00%0.00%0.00%-25.20%-77.68%CBIOCatalyst Biosciences0.00%0.00%0.00%0.00%+3,191.63%CORVCorrevio Pharma0.00%0.00%0.00%0.00%0.00%IFRXInflaRx0.00%+7.51%-11.69%-9.33%-71.06%SVRASavara-9.59%-14.52%-12.03%-14.86%+136.87%Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACBIOCatalyst BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACORVCorrevio PharmaN/AN/AN/AN/AN/AN/AN/AN/AIFRXInflaRx2.9293 of 5 stars3.85.00.00.00.01.71.3SVRASavara3.0977 of 5 stars3.55.00.00.02.61.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLCMBellicum PharmaceuticalsN/AN/AN/AN/ACBIOCatalyst BiosciencesN/AN/AN/AN/ACORVCorrevio PharmaN/AN/AN/AN/AIFRXInflaRx3.50Strong Buy$13.50871.22% UpsideSVRASavara3.00Buy$8.2084.27% UpsideCurrent Analyst RatingsLatest SVRA, BLCM, CORV, CBIO, and IFRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$8.003/22/2024IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/4/2024SVRASavaraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$7.00 ➝ $16.002/15/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.001/25/2024IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLCMBellicum Pharmaceuticals$1.50M0.48N/AN/A$0.23 per share0.33CBIOCatalyst Biosciences$790K0.00N/AN/A($0.78) per share0.00CORVCorrevio Pharma$32.63M0.85N/AN/A($0.02) per share-21.00IFRXInflaRx$63.09K1,297.33N/AN/A$1.89 per share0.74SVRASavaraN/AN/AN/AN/A$1.04 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLCMBellicum Pharmaceuticals-$24.97MN/A0.00∞N/AN/AN/A-157.93%N/ACBIOCatalyst Biosciences-$8.24M-$1.38N/AN/AN/AN/A-364.68%-281.68%N/ACORVCorrevio Pharma-$35.18M-$0.79N/A∞N/A-107.81%-2,128.82%-58.56%N/AIFRXInflaRx-$46.18M-$0.86N/AN/AN/AN/A-40.10%-36.24%5/9/2024 (Estimated)SVRASavara-$54.70M-$0.33N/AN/AN/AN/A-46.27%-35.94%5/20/2024 (Estimated)Latest SVRA, BLCM, CORV, CBIO, and IFRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023IFRXInflaRx-$0.20-$0.30-$0.10-$0.30N/AN/A3/7/2024Q4 2023SVRASavara-$0.11-$0.09+$0.02-$0.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/ACBIOCatalyst BiosciencesN/AN/AN/AN/AN/ACORVCorrevio PharmaN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLCMBellicum PharmaceuticalsN/A3.043.04CBIOCatalyst BiosciencesN/A2.882.88CORVCorrevio Pharma22.541.070.95IFRXInflaRxN/A6.505.82SVRASavara0.1915.6615.66OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLCMBellicum Pharmaceuticals4.93%CBIOCatalyst Biosciences5.98%CORVCorrevio Pharma7.30%IFRXInflaRx42.39%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipBLCMBellicum Pharmaceuticals10.30%CBIOCatalyst Biosciences2.92%CORVCorrevio PharmaN/AIFRXInflaRx16.30%SVRASavara4.58%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLCMBellicum Pharmaceuticals139.72 million8.72 millionNot OptionableCBIOCatalyst Biosciences737.98 million36.87 millionOptionableCORVCorrevio Pharma13366.19 millionN/AOptionableIFRXInflaRx6258.88 million49.29 millionOptionableSVRASavaraN/A138.15 million131.82 millionOptionableSVRA, BLCM, CORV, CBIO, and IFRX HeadlinesSourceHeadlineSavara (NASDAQ:SVRA) Trading Down 6.6%marketbeat.com - April 24 at 6:51 PMSavara Inc (NASDAQ:SVRA) Shares Acquired by Jennison Associates LLCmarketbeat.com - April 24 at 7:27 AMJMP Securities Reiterates "Market Outperform" Rating for Savara (NASDAQ:SVRA)americanbankingnews.com - April 20 at 1:54 AMFYBR, BCRX and SABR are among after hour moversseekingalpha.com - April 20 at 1:53 AMSavara's (SVRA) Market Outperform Rating Reiterated at JMP Securitiesmarketbeat.com - April 18 at 2:21 PMSavara (NASDAQ:SVRA) Trading Down 3.9%marketbeat.com - April 17 at 12:20 PMSavara (NASDAQ:SVRA) Sees Large Volume Increasemarketbeat.com - April 15 at 1:54 PMVanguard Group Inc. Buys 789,249 Shares of Savara Inc (NASDAQ:SVRA)marketbeat.com - April 14 at 4:16 AMSavara Calls Out Haters!ghettoradio.co.ke - April 13 at 12:23 PMSavara (NASDAQ:SVRA) Shares Up 3.6%marketbeat.com - April 11 at 1:47 PMOptimistic Buy Rating for Savara Based on Molgramostim’s Market Potential and Study Outcomesmarkets.businessinsider.com - April 11 at 8:38 AMSavara (NASDAQ:SVRA) Trading Up 2.6%marketbeat.com - April 4 at 12:45 AMDetails of Savara’s Upcoming Projectsghettoradio.co.ke - March 27 at 5:19 AMSavara Announces New Employment Inducement Grantbusinesswire.com - March 22 at 4:05 PMSavara: Why Sauti Sol had to take a break from each othermpasho.co.ke - March 19 at 4:25 AMSavara Inc. Reports Increased Expenses, Anticipates Positive Data from IMPALA-2 Trialmsn.com - March 13 at 1:33 PMFDA lifts partial hold on Nurix Phase 1 study for NX-2127msn.com - March 11 at 6:57 PMBuy Rating Affirmed: Anticipating IMPALA-2 Trial Success and aPAP Treatment Breakthrough with Molgramostimmarkets.businessinsider.com - March 11 at 1:57 PMSVRA Jul 2024 7.500 callfinance.yahoo.com - March 10 at 9:20 AMOptimistic Buy Rating for Savara on Molgramostim’s Market Potential and Strong Financialsmarkets.businessinsider.com - March 8 at 9:43 AMSVRA Stock Earnings: Savara Beats EPS for Q4 2023msn.com - March 7 at 11:08 PMSavara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Updatefinance.yahoo.com - March 7 at 6:08 PMBest penny stocks of March 2024usatoday.com - March 6 at 4:44 PMSavara to Present at the Barclays 26th Annual Global Healthcare Conferencefinance.yahoo.com - March 6 at 4:44 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBellicum PharmaceuticalsNASDAQ:BLCMBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.Catalyst BiosciencesNASDAQ:CBIOCatalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.Correvio PharmaNASDAQ:CORVCorrevio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.InflaRxNASDAQ:IFRXInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.SavaraNASDAQ:SVRASavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.